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A B S T R A C T
In the present study we used two groups of Candida dubliniensis strains: one containing 
fluconazole-susceptible clinical isolates and another containing fluconazole-resistant 
laboratory derivative from the former to examine the changes on susceptibility 
accompanying the development of resistance to fluconazole. Our findings confirmed the 
ability of C. dubliniensis isolates to become resistant to fluconazole and indicated that this 
resistance was crossed with ketoconazole, itraconazole, ravuconazole and terbinafine. 
We also tested combinations of terbinafine, amphotericin B, itraconazole and voriconazole 
against both groups of isolates in a checkerboard assay. Surprisingly, most combinations 
evidenced indifferent interactions, and the best synergism appeared when terbinafine and 
itraconazole were combined against the fluconazole-resistant group. 
The increasing incidence of fungal infections without a 
satisfactory response to the current antifungal therapy and 
the slow development of new agents with novel mechanisms 
of action have produced significant interest on associations 
between antifungal agents.1 Achievement of synergy is one of 
the major theoretical justifications for combination therapy, 
since it may enable practitioners to diminish drug dosages, 
expand the coverage in seriously ill patients with mixed 
infections and delay emergence of resistant mutants. On the 
other hand, cost of therapy may increase, the chance of drug 
reactions is greater, one drug may antagonize the effect of the 
other, and the combination may accomplish no more than one 
effective drug.2 
Since Candida spp. are the most common cause of fungal 
infections, it stands to reason that Candida albicans has been the 
Candida spp. most commonly evaluated in the majority of in vitro 
antifungal combination studies. While the combination of azoles 
with amphotericin B has provided controversial results,3 most 
of studies have found additive or synergistic effect when azoles 
were combined with terbinafine against C. albicans.4-6 Other 
Candida spp. have also been evaluated,5 but little is known about 
the effects of antifungal combinations against Candida dubliniensis.
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C. dubliniensis resembles C. albicans in many phenotypic 
aspects and assumes importance since it is often associated 
with mucocutaneous candidiasis especially in HIV-infected 
patients, showing a pathogenic character of this group.7 
Although previous studies indicate that most strains of 
C. dubliniensis are susceptible to the same antifungal spectrum, 
clinical fluconazole-resistant isolates have been reported.8 
In order to search for new alternative therapies, the aim of 
this study was to evaluate in vitro effects of the combination 
terbinafine and amphotericin B with azoles against fluconazole-
sensitive (FS) and -resistant (FR) strains of C. dubliniensis. 
We used two groups of C. dubliniensis strains: the first 
included clinical fluconazole-susceptible isolates recovered 
from AIDS-patients. The second group included fluconazole-
resistant derivatives obtained from the first through an in 
vitro method of induction of fluconazole resistance described 
by Fekete-Forgács et al.9 as follows: a 10 mL culture of the 
FS strain was grown overnight in Sabouraud glucose broth 
(SDB). Cells were added to flasks containing 20 mL of SDB to 
achieve a final absorbance of 0.1 (λ = 640 nm). The culture was 
incubated at 30°C for 10h, and then fluconazole was added at a 
final concentration of 8 µg/mL (higher than the MIC, Table 1). 
After 14h of further incubation the cells of the fluconazole-
containing culture were subcultured three times consecutively 
into fresh SDB containing 8 µg/mL fluconazole and in each case 
were incubated at 30°C with shaking for 24h. After the third 
incubation cells were added to flasks containing 20 mL of SDB 
containing fluconazole 8 µg/mL to achieve a final absorbance 
of 0.1. After 10h incubation the fluconazole was added at a final 
concentration of 16 µg/mL, and after 14h of further incubation 
the cells of this culture were subcultured three times into 
fresh SDB containing fluconazole 16 µg/mL and incubated in 
each case at 30°C with shaking for 24h. The concentration of 
fluconazole was always duplicated under the procedure;  the 
final concentration was 64 µg/mL. Cells from this culture were 
plated, and single colony was designated isolate FR.
Voriconazole (Pfizer Inc. – New York, NY, USA), itraconazol 
(Janssen-Cilag Pharmaceutica – Belgium) amphotericin B 
and fluconazole (Sigma Chemical Co. – St. Louis, MO, USA) 
and terbinafine (Novartis) were obtained as standard powders 
and prepared according to Clinical and Laboratory Standards 
Institute guidelines.10
Antifungal combinations against the two groups of isolates 
were tested in duplicate using checkerboard method. After 
determination of the MIC of each drug alone,10 dilutions were 
prepared in order to obtain four-fold the final concentrations: 
50 mL- aliquots of each azole dilution were combined with 
other 50 mL of either amphotericin B or terbinafine dilutions. 
Then, 100 mL of inoculum were transferred to each well. Inocula 
preparation, time and temperature of incubation, and reading 
were similar to those described for MIC determination.10
To evaluate the interaction of agents, the fractional inhibitory 
concentration index (FICI) was calculated for each combination. 
Fractional inhibitory concentration (FIC) was calculated for 
each agent by dividing the inhibitory concentration of each 
antifungal agent when used in combination by its MIC. FIC 
values were then added together to define the interaction of 
the combination. Synergy was defined as an FICI ≤ 0.5, additive 
effect when 0.5 < FICI < 1.0, indifference when 1.0 ≤ FICI < 4.0, 
and antagonism when FICI ≥ 4.0.
Broth microdilution MICs of antifungals alone were 
determined against the isolates before and after 15 days of 
increased exposure to fluconazole. Geometric means are 
presented in Table 1. Results demonstrate that, besides 
fluconazole, resistant derivatives were less susceptible to the 
rest of antifungals when compared to sensitive strains. 
Table 2 depicts the interactions of azoles with terbinafine 
or amphotericin B by checkerboard method. The majority 
of combinations had indifferent activity against FS and 
FR C. dubliniensis isolates. However, when interactions 
were detailed for each isolate, it was possible to note that 
almost 67% of FS isolates evidenced antagonism for the 
TRB+ITZ association. Against TRB+VRZ, FS group showed 
similar percentages for synergy and indifference, but 
antagonism still remained the most frequent. On the other 
hand, more positive interactions were obtained when the 
same azoles were combined with AMB. While 46.67% of 
isolates presented antagonism against AMB+VRZ, only 
20% evidenced the same effect when AMB and VRZ were 
combined.
Against FR isolates, antagonistic interactions decreased to 
20% when TRB and ITZ were combined, whereas synergy and 
indifference interactions became more prevalent. TRB+VRZ 
resulted on 53.33% of indifference and synergy decreased 
Agents Group of isolates Geometric mean Range MIC50 MIC90
Amphotericin B
FS
FR
0.207
0.912
0.060-0.50
0.250-2.00
0.250
1.000
0.500
2.000
Fluconazole
FS
FR
0.2145
151.47
0.06-0.50
64-256
0.125
128
0.5
256
Itraconazole
FS
FR
0.033
111.4
0.008-0.25
32.00-512
0.125
4.000
0.500
8.000
Terbinafine
FS
FR
0.771
157.6
0.060-16.0
64.00-256
0.125
8.000
0.250
16.00
Voriconazole
FS
FR
0.006
2.047
0.001-0.125
0.250-16.0
1.000
128.0
4.000
256.0
Table 1 - In vitro susceptibilities (mg/mL) of C. dubliniensis isolates to antifungal agents before (FS) and after (FR)  
15 days of increased exposure to fluconazole
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to zero. However, when VRZ was combined with AMB, 60% 
of isolates showed an additive effect. Against AMB+ ITZ, 
13.33% of synergy was obtained, but indifference was the 
most frequent (56.67%).
The increased use of antifungal agents may have contributed 
to the development of highly resistant microorganisms or those 
which are more prone to develop resistance to drugs such 
fluconazole.11 Although most C. dubliniensis clinical isolates 
are susceptible to azole derivatives, resistant strains have been 
recovered from oral cavities of human immunodeficiency virus 
(HIV)-infected patients with oropharyngeal candidiasis and prior 
exposure to fluconazole.8,12 Thus, combining antifungal agents 
has been suggested as an alternative strategy, and the use of 
terbinafine in combination with azoles has been suggested as 
a potential therapeutic option.4-6,13
Despite promising results obtained through some antifungal 
associations against Candida spp., only the combination of 
caspofungin with terbinafine has already been tested against 
C. dubliniensis.14 Differential effects were detected when 
C. albicans and C. dubliniensis were exposed to the same 
antifungal combination; it is acceptable the evidence of 
negative effects against C. dubliniensis. The combination 
of caspofungin and terbinafine appears to result in positive 
interactive effects against C. albicans, whereas against 
C. dubliniensis it did not.14
In this study, we investigated in vitro interactions of 
amphotericin B and terbinafine with azoles against FS and FR 
groups of C. dubliniensis. Against the FS group, the best activity 
was obtained for the combination of amphotericin B with 
voriconazole, which showed 6.66% of synergistic effect and 60% 
of additive effect. Although the best synergy rates (16.66%) were 
obtained for both TRB+VRZ and AMB+ITZ, the latter seemed 
to be better since it showed  half of the antagonism seen 
with the first. Finally, because 66.66% of isolates evidenced 
antagonism when terbinafine and itraconazole were combined, 
it was considered the worst association. Synergy rates (16.66%) 
were low when compared with results obtained by Perea et 
al.,15 Barchiesi et al.,4 Cantón et al.,5 and Weig & Muller,6 who 
found synergistic or addictive interactions when terbinafine 
and azoles were combined against C. albicans strains. 
Against the FR group, TRB+ITZ was the association that 
most frequently resulted in synergy (30%). When terbinafine 
was combined with voriconazole, synergy decreased to zero 
and indifference became the most frequent (53.33%) result. 
AMB+ITZ resulted in indifference in 56.67% of interactions. 
But when amphotericin was combined with voriconazole, an 
additive effect was the most frequent result (60%). 
Although the majority of reports mention antagonism 
between amphotericin B and azoles, data from in vitro 
studies remain controversial, and indifferent and addictive 
inter-actions are also described.3,16 Here, combinations of 
amphotericin B and azoles mostly resulted in indifferent 
interactions against C. dubliniensis in both groups of isolates.
Among the combinations tested, terbinafine with 
itraconazole deserves more attention because this association 
has shown disparate activities: it was the worst combination 
for FS group (66.6% of antagonism) and the best combina- 
tion for FR group (30%). On the other hand, on previous studies, 
terbinafine has improved the in vitro activity of fluconazole 
and itraconazole against FS or FR C. albicans isolates. The 
combination was also very synergistic against clinical isolates 
of Candida glabrata and no antagonism was detected.15
In fact, susceptibility of C. dubliniensis to antifungal 
associations was disappointing and frightening if we consider 
those interactions obtained on previous studies when C. albicans 
strains were tested. If we consider clinical situations in which 
the resistance phenomenon is emergent, careful identification 
of such Candida species and determination of fluconazole 
susceptibility are necessary before practitioners choose to 
treat many mycotic infections with these combinations. Since 
checkerboard method is a preliminary in vitro test, further 
studies are required in order to provide clearer information 
about susceptibility differences between these species when 
exposed to azole-polyene or azole-allylamine combination.
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Agents Group of isolates Interactions
  Synergy Additivity Indifference Antagonism
Terbinafine
Itraconazole
FS
FR
3.33%
30%
3.33%
13.33%
26.66%
36.66%
66.66%
20%
Terbinafine
Voriconazole
FS
FR
16.66%
0%
10%
23.33%
16.66%
53.33%
56.67%
23.33%
Amphotericin B
Itraconazole
FS
FR
16.66%
13.33%
20%
10%
40%
56.67%
23.33%
20%
Amphotericin B
Voriconazole
FS
FR
6.66%
6.66%
16.66%
60%
30%
23.33%
46.67%
6.66%
Table 2 - Individual analysis of interactions resulted from in vitro antifungal combinations of terbinafine, amphotericin B, 
itraconazole and voriconazole against fluconazole-susceptible (FS) and -resistant (FR) C. dubliniensis isolates
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